Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
Anna Galanopoulos1, Ivan Goldberg21Senior Visiting Ophthalmologist, South Australian Institute of Ophthalmology and Dept of Ophthalmology and Visual Sciences, University of Adelaide, South Australia; 2Clinical Associate Professor, University of Sydney, Australia; Head, Glaucoma Unit, Sydney Eye Hosp...
Guardado en:
Autores principales: | Anna Galanopoulos, Ivan Goldberg |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/eb440bd0135d4fe88ba06a90c277e32b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension
por: Sharma S, et al.
Publicado: (2015) -
Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension
por: Whitson JT, et al.
Publicado: (2013) -
Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Durán LM, et al.
Publicado: (2012) -
Preliminary results following the use of a fixed combination of timolol–brimonidine in patients with ocular hypertension and primary open-angle glaucoma
por: Dimitris Papaconstantinou, et al.
Publicado: (2009) -
Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension
por: Wang N, et al.
Publicado: (2020)